COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
R. STAHL Supervisory Board appoints Tobias Popp member of the Executive Board
R. STAHL Supervisory Board appoints Tobias Popp as Chief Commercial Officer, responsible for Sales, Marketing & Portfolio and IT, effective 1 September 2024. Demonstrates continuity and strategic focus -
-
COMMUNIQUÉ DE PRESSE
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Pierre et Vacances releases information on total number of shares and voting rights as of May 31, 2024, in compliance with French regulations -
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking microdosing depression trial with MB22001, showing significant reductions in anxiety, stress, and depression -
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking depression trial using microdoses of psychedelic medicines, showing significant improvements in anxiety, stress, and depression levels -
COMMUNIQUÉ DE PRESSE
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens
Biophytis annonce le succès du transfert industriel de production de BIO101 (20-hydroxyecdysone) par son prestataire Seqens. La société se focalise sur le traitement de maladies liées à l'âge, notamment la Dystrophie Musculaire de Duchenne -
COMMUNIQUÉ DE PRESSE
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients
